14 Nov, EOD - Indian

SENSEX 77580.31 (-0.14)

Nifty 50 23532.7 (-0.11)

Nifty Bank 50179.55 (0.18)

Nifty IT 42390.85 (0.05)

Nifty Midcap 100 54043.1 (0.45)

Nifty Next 50 67408.65 (0.46)

Nifty Pharma 21752 (-0.26)

Nifty Smallcap 100 17601.05 (0.81)

14 Nov, EOD - Global

NIKKEI 225 38314.38 (-0.85)

HANG SENG 19744.79 (1.64)

S&P 5922 (0.23)

Login/Signup
LOGIN HERE
Cancel

Advanced Enzyme Technologies Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 540025 | NSE Symbol : ADVENZYMES | ISIN : INE837H01020 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
30-Oct-2024 09-Nov-2024 Quarterly Results Quarterly Results Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 ,inter alia, to consider and approve Meeting of Board of Directors of the Company is scheduled to be held on Saturday, November 09, 2024, inter alia, to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2024. (As Per BSE Announcement dated on 30.10.2024) With reference to the notice of Board Meeting dated November 09, 2024, we hereby inform that the Board of Directors at its Meeting held on November 09, 2024 has inter-alia approved the Unaudited Financial Results (Standalone & Consolidated ) of the Company for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 09.11.2024)
02-Aug-2024 10-Aug-2024 Quarterly Results Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve This is to inform that the Meeting of Board of Directors of Company is scheduled to be held on Saturday August 10 2024 inter alia to consider and approve Un-audited Financial Results(Standalone and Consolidated) of the Company for the quarter ended June 30 2024. Further to our letter dated June 28 2024 intimating closure of Trading Window we wish to inform you that the Trading Window for dealing in the Securities of the Company will continue to remain closed up to August 12 2024 Copy of this intimation / notice is also being uploaded on the website of the Company at www.advancedenzymes.com and can be accessed on the website of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com. This is to inform you that the Board of Directors at its Meeting held on August 10, 2024 has inter alia, approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2024. Read less.. (As Per BSE Announcement Dated on 10.08.2024)
06-May-2024 11-May-2024 Final Dividend Dividend & Audited Results & Quarterly Results This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, May 11, 2024 inter-alia to consider the following: (i) to consider & approve annual financial statements (Standalone and consolidated) of the Company for financial year ended March 31, 2024 along with results of the fourth quarter; (ii) to consider & recommend Final Dividend if any for the financial year ended March 31, 2024 and/or consider and declare Interim Dividend if any, for the financial year ended March 31, 2025. Record date for determining the shareholders for the payment of the aforesaid Interim Dividend for FY 2024-25, if any declared by the Board of Directors of the Company shall be Saturday, May 18, 2024 (As Per BSE Announcement Dated on 04/05/2024) The Board of Directors of the Company, Recommended a Final Dividend @55% i.e. 1.1 /- per Equity share on the face value ?2 /- each for the financial year 2023-24, subject to the approval of the Shareholders at the ensuing 35th Annual General Meeting of the Company. The Company has informed the Exchange about the Outcome of the Board Meeting held on May 11, 2024; 1) Financial Results 2) Final Dividend 3) Interim Dividend Declared an Interim Dividend @ 200% i.e. Rs. 4/- per Equity Share on the Face Value of Rs. 2/- each for the Financial Year 2024-25 (As Per BSE Announcement Dated on 11.05.2024) Declared an Interim Dividend @ 200% i.e. 4/- per Equity Share on the face value of 2/- each for the financial year 2024-25. The Interim Dividend for Financial Year 2024-25 will be paid to those shareholders whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares determined with reference to the Record Date of May 18, 2024 (Saturday), already announced for the said purpose by the Company vide letter dated May 04, 2024. The aforesaid Interim Dividend will be paid to the Shareholders on or before June 05, 2024. (As Per BSE Announcement PDF Dated on 11.05.2024)
03-Feb-2024 10-Feb-2024 Quarterly Results Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31 2023. This is to inform you that the Board of Directors at its Meeting held on February 10, 2024 has inter alia, approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2023 and acquisition of an additional stake of upto 5.89% of JC Biotech Private Limited Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2023 (As Per BSE Announcement Dated on 10.02.2024)
31-Oct-2023 07-Nov-2023 Quarterly Results Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30 2023 With reference to the notice of Board Meeting dated October 31, 2023, we hereby inform that the Board of Directors at its Meeting held on November 07, 2023 (commenced at 11.25 a.m. and concluded at 11.55 a.m.) has inter alia, approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2023. In view of the aforesaid, we are enclosing Annexure I - Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2023 along with the Limited Review report issued by MSKA & Associates, Statutory Auditors of the Company as an Annexure. The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com This is for your information and for public at large. with reference to the notice of Board Meeting dated October 31, 2023, we hereby inform that the Board of Directors at its Meeting held on November 07, 2023 has inter-alia approved the unaudited financial results (Standalone & Consolidated ) of the Company for the quarter and half year ended September 30, 2023. Outcome of Board Meeting held on November 07, 2023 (As Per BSE Announcement Dated on 07.11.2023) Extract of Un-audited Consolidated Financial Results for the quarter and half year ended September 30, 2023, published in The Free Press Journal and Navshakti on November 08, 2023 (As Per BSE Announcement Dated on 08.11.2023)
04-Aug-2023 12-Aug-2023 Quarterly Results Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30 2023. With reference to the notice of Board Meeting dated August 04, 2023, we hereby inform that the Board of Directors at its Meeting held on August 12, 2023 (commenced at 10.05 a.m. and concluded at 10.45 a.m.) has inter alia, approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023. In view of the aforesaid, we are enclosing the following: - Annexure I - Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2023 along with the Limited Review report issued by MSKA & Associates, Statutory Auditors of the Company as an Annexure. The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com Statement of Unaudited Standalone and Consolidated Financial Results of the Company for the Quater ended 30th June 2023 (As Per BSE Announcement Dated on 12/08/2023)
06-May-2023 13-May-2023 Accounts Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2023 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Saturday May 13 2023 inter alia to consider the following: To consider & approve annual Financial Statements (Standalone & Consolidated) of the Company for the financial year ended March 31 2023 along with results of the fourth quarter; To consider & recommend Final dividend if any for the financial year ended March 31 2023 and/or to consider & declare Interim Dividend if any for the financial year ended 2023-24. The Record date for determining the shareholders for the payment of the aforesaid Interim Dividend for FY2023-24 if any declared by the Board of Directors of the Company shall be Saturday May 20 2023. Closure of Trading Window: Further to our letter dated March 28 2023 intimating closure of Trading Window we wish to inform you that the Trading Window for dealing in the Securities of the Company will continue to remain closed up to May 15 2023. Approved the Audited Financial Statements (Standalone and Consolidated) of the Company for the financial year ended March 31, 2023 along with fourth quarter results. Recommended a Final Dividend @ 50% i.e. Re. 1/- per Equity Share on the face value of Rs. 2/- each for the financial year 23, subject to the approval of the Shareholders at the ensuing 34th Annual General Meeting of the Company ('AGM').The Final Dividend, if approved / declared by the Shareholders at 34th AGM, will be paid on and from the second day from the date of AGM. Declared an Interim Dividend @ 200% i.e. Re. 4/- per Equity Share on the face value of Rs. 2/- each for the financial year 2023-24. Declared an Interim Dividend @ 200% i.e. Re. 4/- per Equity Share on the face value of Rs. 2/- each for the financial year 2023-24. The Interim Dividend for Financial Year 2023-23 will be paid to those shareholders whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares determined with reference to the Record Date of May 20, 2023 (Saturday), already announced for the said purpose by the Company vide its letter dated May 06, 2023. The aforesaid Interim Dividend will be paid to the Shareholders on or before June 11, 2023. Recommended a Final Dividend @ 50% i.e. Re. 1/- per Equity Share on the face value of Rs. 2/- each for the financial year 2022-23, subject to the approval of the Shareholders at the ensuing 34th Annual General Meeting of the Company ('AGM'). The Final Dividend, if approved / declared by the Shareholders at 34th AGM, will be paid on and from the second day from the date of AGM. Record date for the entitlement of Final Dividend, and date & timings for ensuing Annual General Meeting of the Company shall be intimated in due course of time. Advanced Enzyme Technologies Limited has informed the Exchange about the Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2023 along with the Auditor''s Report issued by MSKA & Associates, Statutory Auditors of the Company The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com Change in Directorate (As Per BSE Announcement Dated on 13.05.2023)
04-Feb-2023 11-Feb-2023 Quarterly Results Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2023 ,inter alia, to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2022. With reference to the notice of Board Meeting dated February 04, 2023, we hereby inform that the Board of Directors of the Company at its meeting held on February 11, 2023 (commenced at 11.25 a.m. and concluded at 12.10 p.m.) has inter alia, transacted the following business: Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2022. Approved the allotment of 2,000 Equity Shares of face value of Rs. 2/- at an exercise price of Rs. 60/- per share pursuant to exercise of options under the Employees Stock Option Scheme, 2015. In view of the aforesaid, we are enclosing the following: Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2022 along with the Limited Review report issued by MSKA & Associates, Statutory Auditors of the Company, as Annexure I to this letter. This is for your information and for public at large. With reference to the notice of Board Meeting dated February 04, 2023, we hereby inform that the Board of Directors of the Company at its meeting held on February 11, 2023 (commenced at 11.25 a.m. and concluded at 12.10 p.m.) has inter alia, transacted the following business: Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2022. Approved the allotment of 2,000 Equity Shares of face value of Rs. 2/- at an exercise price of Rs. 60/- per share pursuant to exercise of options under the Employees Stock Option Scheme, 2015. In view of the aforesaid, we are enclosing the following: Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2022 along with the Limited Review report issued by MSKA & Associates, Statutory Auditors of the Company, as Annexure I to this letter. This is for your information and for public at large. The Company has informed that the Board of Directors in its meeting held on February 11, 2023 has approved the allotment of 2,000 Equity Shares of face value of Rs. 2/- at an exercise price of Rs. 60/- per share pursuant to exercise of options under the Employees Stock Option Scheme, 2015. We hereby inform that the Board of Directors of the Company at its said meeting held on February 11, 2023 inter alia, took note of the following: Approval of the Board of respective wholly owned subsidiaries i.e. Dynamic Enzymes, Inc., USA ('DE') and Advanced Supplementary Technologies Corporation, USA ('AST') regarding the proposed merger of DE and AST. DE and AST are direct wholly owned subsidiaries of Advanced Enzymes USA Inc. ('AEU') and AEU is a direct wholly owned subsidiary of Advanced Enzyme Technologies Limited ('AETL'). Pursuant to the approval of the respective Boards' as mentioned above, DE will be merged with and into AST and consequently DE will cease to exist. (As Per BSE Announcement Dated on 11.02.2023)
04-Nov-2022 11-Nov-2022 Quarterly Results Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30 2022. With reference to the Board meeting notice dated November 04, 2022, we hereby inform that the Board of Directors in its meeting held on November 11, 2022 (commenced at 11:15 a.m. and concluded at 12:15 p.m.) has inter-alia, approved the Unaudited Financial Results of the Company (Standalone & Consolidated) for the quarter and half year ended September 30, 2022. In view of the aforesaid, we hereby enclose the following: Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2022 along with the Limited Review Report issued by M S K A & Associates, Statutory Auditors of the Company. This is for your information and for public at large. we hereby inform that the Board of Directors of the Company at its said meeting held on November 11, 2022 inter alia, approved the following: A)Acquisition of 50% stake of SAIGANESH ENZYTECH SOLUTIONS PRIVATE LIMITED by way of subscription to the issue of upto 19,991,663 Equity Shares as may be offered on private placement/preferential issue basis by SESPL at a total consideration not exceeding Rs. 60 million, and authority for signing of Share Purchase Agreement in this regard B)Acquisition of an additional stake of upto 4.83% of JC Biotech Private Limited (existing 85% subsidiary) by way of purchase of upto 1,000,000 Equity Shares from one of the existing shareholder of JC Biotech at a total consideration not exceeding Rs. 68 million C)Conversion of loan including interest, as was earlier granted by the Company to Advanced Enzymes Europe B.V., Netherlands, an existing wholly owned subsidiary of the Company into Equity Shares of AEE (further acquisition of equity shares in AEE) (As Per BSE Announcement dated on 11.11.2022)
30-Jul-2022 06-Aug-2022 Quarterly Results Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2022 inter alia to consider and approve Advanced Enzyme Technologies Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2022 inter alia to consider and approve un-audited financial results (Standalone & Consolidated) of the Company for the quarter ended June 30 2022 With reference to the Board meeting notice dated July 30, 2022, we hereby inform that the Board of Directors in its meeting held on August 06, 2022 (commenced at 10:00 a.m. and concluded at 10:45 a.m.) has inter-alia, approved the Unaudited Financial Results of the Company (Standalone & Consolidated) for the quarter ended June 30, 2022. In view of the aforesaid, we hereby enclose the following: Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2022 along with the Limited Review Report issued by M S K A & Associates, Statutory Auditors of the Company. This is for your information and for public at large. (As Per BSE Announcement Dated on 06/08/2022)
21-Jul-2022 21-Jul-2022 Employee Stock Option Pursuant to the provisions of Regulation 30 and other applicable provisions of the SEBI Listing Regulations, this is to inform that the Board of Directors of the Company ('Board'), at its meeting held on July 21, 2022, considered and approved 'AETL - Employee Stock Option Scheme 2022' ['Scheme'], subject to the approval of the Shareholders at the ensuing 33rd Annual General Meeting ('AGM') of the Company and other approvals, as may be required. The disclosure pursuant to the SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed.
12-May-2022 20-May-2022 Accounts Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 inter alia to consider and approve Advanced Enzyme Technologies Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 inter alia to consider and approve Annual Financial Statements (Standalone & Consolidated) of the Company for the financial year ended March 31 2022 along with results of the fourth quarter and to consider approve and recommend Final dividend if any for the financial year ended March 31 2022 With reference to the Board meeting notice dated May 12, 2022, we hereby inform that the Board of Directors in its meeting held on May 20, 2022 (commenced at 11:00 a.m. and concluded at 11:45 a.m.) has inter-alia, transacted the following business : Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2022 along with the Auditor's Report issued by MSKA & Associates, Statutory Auditors of the Company. Recommended a Dividend @ 50% i.e. Rs. 1/- per equity share on the face value of Rs. 2/- each for the financial year ended March 31, 2022, subject to the approval of the Shareholders at the ensuing 33rd Annual General Meeting of the Company (''AGM''). Allotted 5,900 Equity Shares of face value of Rs. 2/- at an exercise price of Rs. 60/- per share pursuant to exercise of options under the Employees Stock Option Scheme, 2015. This is for your information and for public at large. (As Per BSE Announcement Dated on 20.05.2022)
30-Mar-2022 30-Mar-2022 Change in Directors This is to inform you that the Board of the Company at their meeting held today, has appointed Mr. Nitin Jagannath Deshmukh (DIN: 00060743) as an Additional Director (Independent), with effect from July 01, 2022, to hold office up to the date of ensuing AGM or the date up to which AGM shall be held, whichever is earlier. Subject to approval of the Members at the ensuing AGM of the Company, Mr. Nitin Deshmukh shall hold office as an Independent Director for a period of 5 (five) years effective from July 01, 2022. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are annexed. Further, we would like to inform that consequent to attaining retirement age (as per the Company's policy), the Board extended the tenure of Mr. Beni P Rauka as CFO (Key Managerial Personnel) of the Company for a period of 10 years from April 01, 2022 till March 31, 2032.
28-Jan-2022 05-Feb-2022 Quarterly Results Quarterly Results With reference to the Board meeting notice dated January 28, 2022, we hereby inform that the Board of Directors in its meeting held on February 05, 2022 (commenced at 10:55 a.m. and concluded at 11:30 a.m.) has inter-alia, approved the Unaudited Financial Results of the Company (Standalone & Consolidated) for the quarter and nine months ended December 31, 2021. In view of the aforesaid, we hereby enclose the following: Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2021 along with the Limited Review Report issued by M S K A & Associates, Statutory Auditors of the Company. Allotted 9,200 Equity Shares of face value of Rs. 2/- at an exercise price of Rs. 60/- per share pursuant to exercise of options under the Employees Stock Option Scheme, 2015. This is for your information and for public at large. (As Per BSE Announcement Dated on 05.02.2022)
26-Oct-2021 02-Nov-2021 Quarterly Results Quarterly Results Advanced Enzyme Technologies Limited has informed the Exchange about the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2021 along with the Limited Review report issued by M S K A & Associates, Statutory Auditors of the Company. (As Per BSE Announcement Dated 02.11.2021)
1 2